Certa Therapeutics Is A Biotechnology Company Dedicated To Developing Precision Therapies For Fibrotic Diseaseswhich Are Significant Contributors To Global Mortalitythe Company Focuses On Conditions Such As Systemic Sclerosischronic Kidney Diseasediabetic Nephropathyand Focal Segmental Glomerulosclerosiscerta Aims To Disrupt Fibrotic Pathways By Creating Small Molecule Inhibitors Of Gpr68A Receptor That Plays A Crucial Role In Inflammation And Tissue Scarring One Of Certa S Key Products Is Ft011Asengeprast Which Targets Systemic Sclerosis And Has Completed A Multinational Phase Ii Trialthis Therapy Has Received Fda And Ema Orphan Drug Designation For Scleroderma And Works By Reversing Inflammatory And Fibrotic Pathwayscerta Is Also Advancing Additional Programs For Chronic Kidney Disease And Focal Segmental Glomerulosclerosiswith Plans For Phase Ii Studies And The Development Of Companion Diagnostics To Identify Suitable Patients Based On Genetic And Biomarker Analysis
